Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

When Corporate Integrity Agreements Multiply, Firms Know What To Expect

This article was originally published in The Gray Sheet

Executive Summary

Orthopedic companies will likely be among the next device firms subject to corporate integrity agreements with the HHS Office of Inspector General, and stakeholders say there are clues as to what they should expect

You may also be interested in...



Ortho Industry Reaches $311 Mil. Settlement With DoJ On Kickback Charges

Four major hip and knee implant manufacturers will pay the government a total of $311 million to settle anti-kickback claims resulting from a two-year Department of Justice and HHS investigation into the companies' financial relationships with surgeons, the New Jersey U.S. Attorney's office announced Sept. 27

Ortho Industry Reaches $311 Mil. Settlement With DoJ On Kickback Charges

Four major hip and knee implant manufacturers will pay the government a total of $311 million to settle anti-kickback claims resulting from a two-year Department of Justice and HHS investigation into the companies' financial relationships with surgeons, the New Jersey U.S. Attorney's office announced Sept. 27

Biomet subpoena

Orthopedic firm and U.S. Attorney's office in New Jersey begin discussions of a potential resolution to a Department of Justice investigation into Biomet's relationships with surgeons, the firm discloses in a July 9 SEC filing. Justice has been looking into Biomet's consulting and professional service agreements, as well as research agreements and other grants, with potential orthopedic surgeon customers for the company's hip and knee implants from 1998 to the present (1"The Gray Sheet" June 25, 2007, p. 13). "The results of any resolution remain uncertain at this time, but could, among other things, require monetary payments, cause the company to significantly change some of its existing business practices, and include the potential for additional governmental oversight," Biomet says...

Related Content

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel